.Nature Medicine, Released online: 03 September 2024 doi:10.1038/ s41591-024-03223-zThis Viewpoint requires incorporation of individuals with MASLD and measurement of liver results in cardio-- renal-- metabolic trials, when data recommend mechanistically probable perks as well as scientific protection-- and also outlines factors to consider for trial design as well as governing approval.